Argos Therapeutics reports fourth quarter and year-end 2014 financial results
Argos Therapeutics reported the net loss attributable to common stockholders was $54.2 million, or $3.12 per share, for the 2014 year end versus a net loss of $33.9 million, or $147.37 per share, in 2013. Revenue was $2.0 million at the 2014 year end versus $4.4 million at year end 2013. March 30, 2015